Presentations & Publications

igm-news-hero-03

Presentations & Publications

Delivery of IL-15 to PD-L1 Expressing Tumors with an Anti-PD-L1 IgM

Cytokine-Based Cancer Immunotherapies Summit – March 24-25, 2021

Read More...

In the Media: Nature Biotechnology – Bispecific Antibodies Poised to Deliver Wave of Cancer Therapies

Citation: Sheridan, C. Bispecific antibodies poised to deliver wave of cancer therapies. Nat Biotechnol 39, 251–254 (2021) https://doi.org/10.1038/s41587-021-00850-6

Read More...

Abstract: Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity

AACR Annual Meeting – April 10-15, 2021 Regular abstract titles, authors, and text released – March 10, 2021

Read More...

Engineering on a Natural Multivalent Antibody Platform: Solving Clinical Challenges with Experimental IgM Therapeutics

ESMO Targeted Anticancer Therapies Virtual Congress 2021 – March 1-2, 2021 Session: Multispecific Biological Constructs – March 2, 2021

Read More...

Endogenous Immunity, Synthetic Immunity and Engineering IgM Therapeutics

Immuno-Oncology 360° – February 23-26, 2021 Bispecifics Plenary Session – February 26, 2021

Read More...

At the Intersection of Science and Engineering: Novel Platform Approach to Immunotherapy with IGM-2323

ESMO Immuno-Oncology Virtual Congress 2020 – December 9-12, 2020 Educational Session: Novel Immunotherapeutic Platforms – December 11, 2020

Read More...

The Anti-Tumor Activity of IGM-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML

62nd American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2020 Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents Abstract Number: 2093, December 6, 2020

Read More...

ASH 2020 Investor Conference Call: Pioneering the Development of Engineered IgM Antibodies

IGM Investor Conference Call Presentation at the 62nd ASH Annual Meeting and Exposition December 5, 2020

Read More...

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

62nd American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2020 Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies Number: 1142, December 5,…

Read More...

Agonist IgM: Anti-Death Receptor 5 IgM Induces Tumor Cell Apoptosis in vitro and in vivo with a Favorable Safety Profile

PEGS Europe Virtual – November 12, 2020 Program: Novel Targets and Emerging Therapeutic Areas

Read More...